PMID- 25292409
OWN - NLM
STAT- MEDLINE
DCOM- 20160728
LR  - 20211021
IS  - 1718-4304 (Electronic)
IS  - 0896-8608 (Print)
IS  - 0896-8608 (Linking)
VI  - 35
IP  - 5
DP  - 2015 Sep-Oct
TI  - Oral Astaxanthin Supplementation Prevents Peritoneal Fibrosis in Rats.
PG  - 506-16
LID - 10.3747/pdi.2013.00317 [doi]
AB  - BACKGROUND: Preventing peritoneal damage during peritoneal dialysis is critical. 
      Reactive oxygen species (ROS) have an important role in peritoneal damage; 
      however, few studies have investigated this. We aimed to determine the effects of 
      oral astaxanthin (AST) supplementation in a peritoneal fibrosis (PF) rat model. 
      METHODS: Thirty-seven Sprague-Dawley rats were divided into 5 groups: Control 1 
      (fed a normal diet without stimulation), Control 2 (fed an AST-supplemented diet 
      without stimulation), Group 1 (fed a normal diet with 8% chlorhexidine gluconate 
      [CG] stimulation for 3 weeks), Group 2 (fed a 0.06% AST-supplemented diet with CG 
      stimulation), and Group 3 (fed a 0.06% AST-supplemented diet that was initiated 4 
      weeks before CG stimulation). Peritoneal fibrosis, vascular proliferation, and 
      fibrosis-related factor expression were examined. RESULTS: Peritoneal thickness 
      was significantly suppressed by AST supplementation. Astaxanthin diminished the 
      number of CD68-, 8-hydroxy-2'-deoxyguanosine (8-OHdG)-, and monocyte 
      chemoattractant protein-1 (MCP-1)-positive cells. Type 3 collagen, tumor necrosis 
      factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), and MCP-1 mRNA expression was 
      significantly lower in Group 3 than in Group 1. Increased transforming growth 
      factor-beta (TGF-beta) and Snail mRNA expression, vascular density, and the number of 
      alpha-smooth muscle actin (alpha-SMA)-positive cells were also decreased in Group 3. 
      CONCLUSION: Astaxanthin suppressed PF development through the inhibition of 
      inflammation and oxidation in PF rats. It appears that the anti-oxidative agent 
      AST may be useful for the prevention of peritoneal damage.
CI  - Copyright (c) 2015 International Society for Peritoneal Dialysis.
FAU - Wakabayashi, Keiichi
AU  - Wakabayashi K
AD  - Division of Nephrology, Department of Internal Medicine, Juntendo University 
      Faculty of Medicine, Tokyo, Japan.
FAU - Hamada, Chieko
AU  - Hamada C
AD  - Division of Nephrology, Department of Internal Medicine, Juntendo University 
      Faculty of Medicine, Tokyo, Japan.
FAU - Kanda, Reo
AU  - Kanda R
AD  - Division of Nephrology, Department of Internal Medicine, Juntendo University 
      Faculty of Medicine, Tokyo, Japan.
FAU - Nakano, Takanori
AU  - Nakano T
AD  - Division of Nephrology, Department of Internal Medicine, Juntendo University 
      Faculty of Medicine, Tokyo, Japan.
FAU - Io, Hiroaki
AU  - Io H
AD  - Division of Nephrology, Department of Internal Medicine, Juntendo University 
      Faculty of Medicine, Tokyo, Japan.
FAU - Horikoshi, Satoshi
AU  - Horikoshi S
AD  - Division of Nephrology, Department of Internal Medicine, Juntendo University 
      Faculty of Medicine, Tokyo, Japan.
FAU - Tomino, Yasuhiko
AU  - Tomino Y
AD  - Division of Nephrology, Department of Internal Medicine, Juntendo University 
      Faculty of Medicine, Tokyo, Japan yasu@juntendo.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141007
PL  - United States
TA  - Perit Dial Int
JT  - Peritoneal dialysis international : journal of the International Society for 
      Peritoneal Dialysis
JID - 8904033
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antioxidants)
RN  - 0 (Ccl2 protein, rat)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Collagen Type III)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Xanthophylls)
RN  - 88847-89-6 (8-Hydroxy-2'-Deoxyguanosine)
RN  - 8XPW32PR7I (astaxanthine)
RN  - G9481N71RO (Deoxyguanosine)
SB  - IM
MH  - 8-Hydroxy-2'-Deoxyguanosine
MH  - Administration, Oral
MH  - Animals
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Antioxidants/*therapeutic use
MH  - Chemokine CCL2/genetics/metabolism
MH  - Collagen Type III/metabolism
MH  - Deoxyguanosine/analogs & derivatives/metabolism
MH  - Disease Models, Animal
MH  - Fluorescent Antibody Technique
MH  - Immunohistochemistry
MH  - Inflammation/drug therapy
MH  - Interleukin-1beta/metabolism
MH  - Male
MH  - Oxidative Stress/drug effects
MH  - Peritoneal Dialysis
MH  - Peritoneal Fibrosis/metabolism/*prevention & control
MH  - Peritoneum/metabolism/*pathology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Real-Time Polymerase Chain Reaction
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Xanthophylls/therapeutic use
PMC - PMC4597983
OTO - NOTNLM
OT  - Anti-inflammation
OT  - anti-oxidant
OT  - astax-anthin
OT  - peritoneal fibrosis
EDAT- 2014/10/09 06:00
MHDA- 2016/07/29 06:00
PMCR- 2017/09/01
CRDT- 2014/10/09 06:00
PHST- 2014/06/09 00:00 [received]
PHST- 2014/07/13 00:00 [accepted]
PHST- 2014/10/09 06:00 [entrez]
PHST- 2014/10/09 06:00 [pubmed]
PHST- 2016/07/29 06:00 [medline]
PHST- 2017/09/01 00:00 [pmc-release]
AID - pdi.2013.00317 [pii]
AID - 10.3747/pdi.2013.00317 [doi]
PST - ppublish
SO  - Perit Dial Int. 2015 Sep-Oct;35(5):506-16. doi: 10.3747/pdi.2013.00317. Epub 2014 
      Oct 7.